Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. (CRDL.TO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
crdl.to · stock forecast · 3 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.54
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.46 | ↓ 5.00% |
1-day model range: $1.46–$1.47. Peak: $1.47 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -26.9% |
| 2028 | $1 | -36.8% |
| 2029 | $1 | -41.0% |
| 2030 | $1 | -43.0% |
| 2031 | — | -44.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRDL.TO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-06 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-02-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Cardiol Therapeutics Inc. (CRDL.TO) stock. Of the recent 17 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover CRDL.TO.
Analyst Recommendation Trends
CRDL.TO analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 96.9% YoY
Revenue Next Year
$4M
↑ 176.1% YoY
EPS This Year
$-0.47
EPS Next Year
$-0.23
↓ 52.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRDL.TO EPS of $-0.47 for the current fiscal year, based on estimates from 4 analysts. The CRDL.TO revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CRDL.TO stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRDL.TO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The CRDL.TO short-term stock prediction for tomorrow is $1.46 (-5.00%). The CRDL.TO stock price prediction for 2027 estimates an average of $1. The CRDL.TO stock prediction for 2030 projects a range of $1–$1.
Cardiol Therapeutics Inc. trades on TSX under the ticker CRDL.TO. The CRDL.TO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
CRDL.TO forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month CRDL.TO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.54.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.